Surface Oncology Overview

  • Founded
  • 2014

Founded
  • Status
  • Public

  • Employees
  • 98

Employees
  • Stock Symbol
  • SURF

Stock Symbol
  • Share Price
  • $0.84

  • (As of Wednesday Closing)

Surface Oncology General Information

Description

Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out through the region of the United States.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 50 Hampshire Street
  • 8th Floor
  • Cambridge, MA 02139
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Surface Oncology Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.84 $0.89 $0.84 - $5.98 $55.3M 60.5M 334K -$1.30

Surface Oncology Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV (39,238) 117,880 322,836 (38,504)
Revenue 30,155 2,687 126,162 15,360
EBITDA (61,963) (74,370) 63,862 (52,859)
Net Income (66,304) (78,485) 59,337 (54,789)
Total Assets 181,621 190,847 217,138 131,693
Total Debt 56,567 57,308 49,269 25,039
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Surface Oncology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Surface Oncology‘s full profile, request access.

Request a free trial

Surface Oncology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Surface Oncology‘s full profile, request access.

Request a free trial

Surface Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces
Drug Discovery
Cambridge, MA
98 As of 2022
00000
000000 - 000 00000

00000

giat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deser
0000 000000000
Gosselies, Belgium
00 As of 0000
00000
0000 0000-00-00
00000000 00000

000000

agna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex e
0000000000000
Cambridge, MA
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Surface Oncology Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
iTeos Therapeutics Formerly VC-backed Gosselies, Belgium 00 00000 00000000 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
000000 00000000000 Formerly VC-backed Burlingame, CA 00 00000 000000 - 000 00000
00000 Formerly VC-backed Cambridge, MA 000 00000 000000&0
00000 00000000000 Formerly VC-backed Hayward, CA 000 00000 000000000 00000
You’re viewing 5 of 30 competitors. Get the full list »

Surface Oncology Patents

Surface Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3160313-A1 Compositions and methods for immunotherapy Pending 15-Nov-2019 00000000000
EP-4058062-A1 Compositions and methods for immunotherapy Pending 15-Nov-2019 00000000000
JP-2022549854-A Anti-il-27 antibody and use thereof Pending 25-Sep-2019
US-20210115127-A1 Anti-il-27 antibodies and uses thereof Pending 25-Sep-2019 0000000000
AU-2020353672-A1 Anti-il-27 antibodies and uses thereof Pending 25-Sep-2019 C07K16/244
To view Surface Oncology’s complete patent history, request access »

Surface Oncology Executive Team (15)

Name Title Board Seat Contact Info
Robert Ross MD President & Chief Executive Officer
Jessica Fees Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Vito Palombella Chief Scientific Officer
Henry Rath Executive
Arlene Sharpe Co-Founder & Scientific Board Advisor
You’re viewing 5 of 15 executive team members. Get the full list »

Surface Oncology Board Members (17)

Name Representing Role Since
Armen Shanafelt Ph.D Lilly Ventures Board Member 000 0000
Benjamin Hickey Self Board Member 000 0000
Carsten Brunn Self Board Member 000 0000
Chris Klee Self Board Observer 000 0000
Daniel Lynch Surface Oncology Chairman & Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

Surface Oncology Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Surface Oncology Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Surface Oncology‘s full profile, request access.

Request a free trial